Pfizer Aktie
WKN: 852009 / ISIN: US7170811035
29.04.2025 13:45:00
|
If You'd Invested $10,000 in Pfizer Stock 10 Years Ago, Here's How Much You'd Have Today
Few would dispute that Pfizer (NYSE: PFE) is an icon within the pharmaceutical world. And, giving credit where it's due, the drugmaker largely led the charge against the COVID-19 pandemic with both a vaccine and treatment.Anyone keeping tabs on this ticker of late, however, likely knows it's also been a disappointment since its contagion-driven peak. Indeed, thanks to more than a 60% pullback from its late-2021 high, investors that committed $10,000 to a position in Pfizer 10 years ago -- when its anti-cholesterol drug Lipitor, arthritis-fighting Enbrel, pneumonia vaccine Prevnar, and nerve pain and epilepsy treatment Lyrica were still firing on all cylinders -- would now be holding just a little over $7,000 worth of this pharmaceutical stock.Things get measurably better when factoring in any reinvested dividends paid in the meantime, though, as the chart below illustrates. The position becomes a net winner, in fact, albeit a small one. All told, reinvesting all the dividends in more shares of this stock as they were paid would leave you with just a tad over $10,600 for the 10-year time frame, although this still trails the broad market's total returns for this stretch by a country mile.Continue readingWeiter zum vollständigen Artikel bei MotleyFool

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Pfizer Inc.mehr Nachrichten
29.04.25 |
Ausblick: Pfizer legt Quartalsergebnis vor (finanzen.net) | |
25.04.25 |
S&P 500-Wert Pfizer-Aktie: Über diese Dividendenzahlung können sich Pfizer-Aktionäre freuen (finanzen.at) | |
22.04.25 |
S&P 500-Titel Pfizer-Aktie: So viel Verlust hätte eine Pfizer-Investition von vor 3 Jahren eingebracht (finanzen.at) | |
15.04.25 |
S&P 500-Papier Pfizer-Aktie: So viel Verlust hätte ein Pfizer-Investment von vor einem Jahr eingebracht (finanzen.at) | |
14.04.25 |
Pfizer-Aktie verliert: Rückschlag - Abbruch der Abnehmpillen-Studie (dpa-AFX) | |
14.04.25 |
ANALYSE-FLASH: JPMorgan belässt Pfizer auf 'Neutral' - Ziel 30 Dollar (dpa-AFX) | |
14.04.25 |
Empfindlicher Rückschlag: Pfizer stoppt Entwicklung von Abnehmpille (Spiegel Online) | |
14.04.25 |
Pfizer stoppt Entwicklung von Abnehmpille nach klinischer Studie (Spiegel Online) |
Analysen zu Pfizer Inc.mehr Analysen
29.04.25 | Pfizer Neutral | UBS AG | |
14.04.25 | Pfizer Buy | Jefferies & Company Inc. | |
14.04.25 | Pfizer Neutral | UBS AG | |
14.04.25 | Pfizer Neutral | JP Morgan Chase & Co. | |
08.04.25 | Pfizer Buy | Jefferies & Company Inc. |
Aktien in diesem Artikel
Pfizer Inc. | 21,02 | 4,14% |
|